Total Payments
$14,745
2024 Payments
$2,626
Companies
71
Transactions
946
Medicare Patients
20,808
Medicare Billing
$10.1M
Payment Breakdown by Category
Food & Beverage$14,560 (98.7%)
Education$184.58 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,560 | 937 | 98.7% |
| Education | $184.58 | 9 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,336 | 95 | $0 (2024) |
| PFIZER INC. | $1,104 | 87 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,016 | 71 | $0 (2024) |
| Genentech USA, Inc. | $848.60 | 66 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $761.58 | 48 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $708.53 | 56 | $0 (2024) |
| Celgene Corporation | $483.25 | 39 | $0 (2024) |
| Lilly USA, LLC | $453.48 | 26 | $0 (2024) |
| ABBVIE INC. | $450.25 | 19 | $0 (2024) |
| GlaxoSmithKline, LLC. | $434.31 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,626 | 139 | Novartis Pharmaceuticals Corporation ($303.49) |
| 2023 | $2,447 | 145 | Novartis Pharmaceuticals Corporation ($222.80) |
| 2022 | $1,880 | 119 | Celgene Corporation ($208.55) |
| 2021 | $1,437 | 84 | PFIZER INC. ($103.02) |
| 2020 | $907.70 | 59 | E.R. Squibb & Sons, L.L.C. ($174.71) |
| 2019 | $1,752 | 124 | Merck Sharp & Dohme Corporation ($185.36) |
| 2018 | $1,988 | 147 | Novartis Pharmaceuticals Corporation ($326.85) |
| 2017 | $1,707 | 129 | Genentech USA, Inc. ($302.16) |
All Payment Transactions
946 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Oncology | ||||||
| 12/27/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Oncology | ||||||
| 12/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.69 | General |
| 12/20/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ADVATE (Biological) | Food and Beverage | In-kind items and services | $30.63 | General |
| Category: HEMATOLOGY | ||||||
| 12/19/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $3.56 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: HEMATOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: HORMONE THERAPY | ||||||
| 11/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Oncology | ||||||
| 11/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $3.38 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $12.55 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.27 | General |
| Category: Hematology/Oncology | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.81 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $11.10 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $8.76 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 68 | 4,605 | 174,539 | $8.4M | $1.9M |
| 2022 | 72 | 5,163 | 279,067 | $10.6M | $2.4M |
| 2021 | 74 | 5,338 | 219,340 | $8.4M | $2.5M |
| 2020 | 73 | 5,702 | 218,371 | $10.7M | $3.3M |
Total Patients
20,808
Total Services
891,317
Medicare Billing
$10.1M
Procedure Codes
287
All Medicare Procedures & Services
287 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 17,600 | $2.8M | $765,065 | 27.7% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 15,360 | $1.4M | $363,745 | 26.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 155 | 192 | $853,824 | $189,944 | 22.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 26 | 5,400 | $345,600 | $99,344 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 386 | 794 | $309,660 | $67,488 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 375 | 880 | $243,760 | $53,585 | 22.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 133 | 620 | $261,020 | $53,057 | 20.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 23 | 2,700 | $199,800 | $43,948 | 22.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 50 | 6,701 | $167,525 | $39,129 | 23.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 36 | 17,420 | $104,520 | $23,994 | 23.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 46 | 55,590 | $222,360 | $22,347 | 10.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 114 | 171 | $94,050 | $21,155 | 22.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 51 | 223 | $46,830 | $16,003 | 34.2% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 11 | 180 | $117,720 | $15,716 | 13.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 157 | 190 | $291,270 | $14,880 | 5.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 682 | 1,853 | $53,737 | $14,047 | 26.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 101 | $60,903 | $13,315 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 68 | 68 | $45,764 | $10,330 | 22.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 61 | 66 | $48,378 | $9,582 | 19.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 43 | 193 | $39,565 | $8,191 | 20.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 94 | 196 | $40,768 | $8,141 | 20.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 127 | 753 | $49,698 | $7,795 | 15.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 197 | 643 | $43,081 | $6,212 | 14.4% |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 2023 | 21 | 13,380 | $26,760 | $5,839 | 21.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 46 | $27,370 | $5,693 | 20.8% |
About Dr. Roy Webb, M.D
Dr. Roy Webb, M.D is a Hematology & Oncology healthcare provider based in Hot Springs, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1346227048.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Webb, M.D has received a total of $14,745 in payments from pharmaceutical and medical device companies, with $2,626 received in 2024. These payments were reported across 946 transactions from 71 companies. The most common payment nature is "Food and Beverage" ($14,560).
As a Medicare-enrolled provider, Webb has provided services to 20,808 Medicare beneficiaries, totaling 891,317 services with total Medicare billing of $10.1M. Data is available for 4 years (2020–2023), covering 287 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hot Springs, AR
- Active Since 12/23/2005
- Last Updated 12/29/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346227048
Products in Payments
- KEYTRUDA (Biological) $908.19
- OPDIVO (Biological) $410.52
- ZEJULA (Drug) $368.77
- XTANDI (Drug) $363.30
- IBRANCE (Drug) $323.16
- KISQALI (Drug) $303.67
- Lenvima (Drug) $289.43
- PROMACTA (Drug) $272.65
- Enhertu (Drug) $255.80
- IMBRUVICA (Drug) $248.48
- LYNPARZA (Drug) $246.08
- JAKAFI (Drug) $228.78
- LIBTAYO (Biological) $221.73
- ORGOVYX (Drug) $209.92
- TECENTRIQ (Biological) $209.30
- Pomalyst (Drug) $203.17
- ELIQUIS (Drug) $199.93
- NINLARO (Drug) $193.67
- MEKINIST (Drug) $188.00
- EPKINLY (Drug) $182.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hot Springs
Lingyi Chen, M.d, M.D
Hematology & Oncology — Payments: $20,958
Hematology & Oncology $20,958
Dr. Robert Muldoon, M.d, M.D
Hematology & Oncology — Payments: $17,778
Hematology & Oncology $17,778
Dr. Amy Cleveland, Md, MD
Hematology & Oncology — Payments: $12,190
Hematology & Oncology $12,190
Cody Williams, Aprn, APRN
Hematology & Oncology — Payments: $9,216
Hematology & Oncology $9,216
Ms. Manjusha Kota, Md, MD
Hematology & Oncology — Payments: $8,292
Hematology & Oncology $8,292